Janney Montgomery Scott LLC Buys 33,951 Shares of Zevra Therapeutics, Inc. $ZVRA

Janney Montgomery Scott LLC grew its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 16.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 236,834 shares of the company’s stock after purchasing an additional 33,951 shares during the quarter. Janney Montgomery Scott LLC owned approximately 0.40% of Zevra Therapeutics worth $2,207,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in ZVRA. Marshall Wace LLP purchased a new stake in Zevra Therapeutics during the 3rd quarter valued at $8,676,000. Rubric Capital Management LP increased its position in shares of Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after acquiring an additional 740,584 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after acquiring an additional 550,000 shares during the last quarter. Nantahala Capital Management LLC raised its stake in shares of Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after acquiring an additional 500,000 shares during the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Zevra Therapeutics during the third quarter worth about $3,980,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $14.75 on Thursday. Zevra Therapeutics, Inc. has a 1 year low of $7.16 and a 1 year high of $15.04. The stock has a market capitalization of $872.02 million, a P/E ratio of 7.41 and a beta of 0.85. The company’s 50-day moving average is $11.95 and its 200 day moving average is $10.15.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The business had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million. Research analysts anticipate that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on ZVRA shares. Guggenheim boosted their price target on Zevra Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Cantor Fitzgerald increased their price objective on Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Canaccord Genuity Group lifted their price objective on Zevra Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a research note on Tuesday, June 23rd. Finally, Maxim Group upped their target price on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.29.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.